Garfield 1 2004 การ ฟ ลด เดอะ ม ฟว 1

���Ѵ���(��) Ẻ���ͧ���Ѫ����ʵ��͡��ҧ��¶١��㹡�è��ͧ�дѺ�� Levofloxacin,Gatifloxacin ��� Moxifloxacin � maxillary sinus 㹡�æ������Ấ�����·�����ä䫹���ѡ�ʺ㹤�������� ~iM.catarrhalis, H.influenzae~i ���~iS.pneumoniae~i �ӹǹ 6 ��¾ѹ��������ͨ������ʡѺ�� Levofloxacin,Gatifloxacin ��� Moxifloxacin 㹤����������ҡѺ����������٧�ش (C(,max))�ҡ��ú������Ҥ������� ��С�ú����������¤��� 㹢�Ҵ�Ѻ��зҹ�ѹ�� 500,400 ��� 400 ����ԡ��� ����ӴѺ �¤�������鹢ͧ�Ҩ�Ŵŧ�����Ҥ��觪��Ե�ͧ�����Ъ�Դ �Ũҡ��÷��ͧ�ʴ����������㹡�ú������� Moxifloxacin ���Gatifloxacin �������� ����ö������ͷ�� 6 ��¾ѹ��������ҧ�Ǵ���� �·����Moxifloxacin ��� Gatifloxacin ����դ�� AUC(,0-24)/MIC ����㹪�ǧ 155.36-189.50��� 125.36-259.12 ����ӴѺ ����դ�� Peak/MIC ����㹪�ǧ 12.14-15.10 ���14.14-28.44 ����ӴѺ ����ö������� ~iS.pneumoniae~i ŧ�� 99.9% �������� 2 ������� �������ö�ӨѴ����������������� 4-6 ������� ���ǡ�����Levofloxacin ����դ�� AUC(,0-24)/MIC ����㹪�ǧ 67.21-1270.80 ����դ�� Peak/MIC ����㹪�ǧ 6.60-145.20 ����Ѻ���� ~iM.catarrhalis~i ��� ~iH.influenzae~i�� Levofloxacin, Gatifloxacin ��� Moxifloxacin ����դ�� AUC(,0-24)/MIC����㹪�ǧ 4515.33-9034.61, 2187.66-19862.85 ��� 1607.80-50420.00 ����ӴѺ����դ�� Peak/MIC ����㹪�ǧ 483.33-919.23, 237.86-1980.00 ��� 116.20-4433.33����ӴѺ �դ�������ö㹡�æ�����ʹѧ���������ҧ�ѹ 㹡�ú����������¤����� Moxifloxacin ��� Gatifloxacin ����դ�� AUC(,0-24)/MIC ����㹪�ǧ 164.14-209.90 ��� 150.66-330.80 ����ӴѺ ����դ�� Peak/MIC ����㹪�ǧ 13.10-15.77��� 16.24-32.96 ����ӴѺ ����ö������� ~iS.pneumoniae~i �����ǡ��ҡ�ú������Ҥ������� ��ǹ�� Levofloxacin ����դ�� AUC(,0-24)/MIC ����㹪�ǧ70.70-1399.40 ����դ�� Peak/MIC ����㹪�ǧ 6.99-137.80 ����㹡�æ�����ʹѧ���������ҧ�Ѻ��ú������Ҥ������� �����ǡѺ���� ~iM.catarrhalis~i��� ~iH.influenzae~i ��ú������� Moxifloxacin ��� Gatifloxacin ���¤��駫���դ�� AUC(,0-24)/MIC ����㹪�ǧ 1653.80-57680.00 ��� 2583.66-22237.14����ӴѺ ����դ�� Peak/MIC ����㹪�ǧ 137.20-4553.33 ��� 292.33-2440.00����ӴѺ ����ö������ʹѧ����������ǡ��ҡ�ú������Ҥ������� ��ǹ��Levofloxacin ����դ�� AUC(,0-24)/MIC ����㹪�ǧ 4340.66-9357.69 ����դ��Peak/MIC ����㹪�ǧ 463.33-967.94 �ʴ���æ�����ʹѧ��������ᵡ��ҧ�Ѻ�������Ҥ������� ��ػ�š�÷��ͧ����ͺ������� Moxifloxacin ��� Gatifloxacin ������������ö������� ~iS.pneumoniae~i �����ǡ����� Levofloxacin �·���������ö㹡�æ������ ~iM.catarrhalis~i ��� ~iH.influenzae~i �ͧ�ҷ�������Դ���ᵡ��ҧ�ѹ �������ͺ����������¤��� �� Moxifloxacin ��� Gatifloxacin����ö������ͷ�� 6 ��¾ѹ�����ա��ҡ�ú������Ҥ������� 㹢�з����Levofloxacin ����ͺ�����㹤���������к����������¤�������㹡�æ�����ͷ�� 6 ��¾ѹ������ᵡ��ҧ�ѹ

���Ѵ���(English) An ~iin vitro~i pharmacokinetic model (IVPM) was used to simulate the peakconcentration (C(,max)) of Levofloxacin, Gatifloxacin and Moxifloxacin in humanmaxillary sinus, when administrate 500, 400 and 400 mg, respectively by oral routonce daily in single dose and multiple doses regimen, against 6 strains ofmicroorganisms causing human maxillary sinusitis such as ~iM.catarrhalis, H.influenzae~iand ~iS.pneumoniae~i. The concentration was decreased depend on the elimination half-lifein each agents. The resu his experiment exhibit the single dose regimen ofMoxifloxacin and Gatifloxacin demonstrated rapid killing of all 6 strains ofmicroorganisms. Moxifloxacin and Gatifloxacin, which have AUC(,0-24)/MIC in the rangeof 155.39-189.50 and 125.36-259.12 respectively and Peak/MIC in the range of12.14-15.10 and 14.14-28.44, respectively could decrease 99.9% viable count of~iS.pneumoniae~i within 2 hours and decrease this microorganism to eradicate within 4-6hours faster than Levofloxacin, which have AUC(,0-24)/MIC in the range of 67.21-1270.80and Peak/MIC in the range of 6.60-145.20. Levofloxacin, Gatifloxacin andMoxifloxacin, which have AUC(,0-24)/ in the range of 4515.33-9034.61, 2187.66-19862.85and 1607.80-50420.00, respectively and Peak/MIC in the range of 483.33-919.23,237.86-1980.00 and 116.20-4433.33, respectively, against ~iM.catarrhalis~i and~iH.influenzae~i demonstrated the similar killing rate for these microorganisms. Themultiple doses regimen of Moxifloxacin and Gatifloxacin, which have AUC(,0-24)/MICin the range of 164.14-209.90 and 150.66-330.80, respectively and Peak/MIC in therange of 13.10-15.77 and 16.24-32.96 respectively, demonstrated the 99.9% viablecount of ~iS.pneumoniae~i decrease which was more than single dose regimen. ForLevofloxacin, which have AUC(,0-24)/MIC in the range of 70.70-1399.40 and Peak/MIC inthe range of 6.99-137.80, demonstrated killing these microorganisms as the same rateas single dose regimen. Moxifloxacin and Gatifloxacin, which have AUC(,0-24)/MIC inthe range of 1653.80-576 80.00 and 2583.66-22237.14 respectively and Peak/MIC in therange of 137.20-4553.33 and 292.33-2440.00 respectively, demonstrated killing~iM.caterrhalis~i and ~iH.influenzae~i faster than single dose regimen. WhileLevofloxacin, which have AUC(,0-24)/ in the range of 4340.66-9357.69 and Peak/MIC inthe range 463.33-967.94, demonstrated killing these microorganisms as the same rateas single dose regimen. The summary, Moxifloxacin and Gatifloxacin single dose regimen demonstratedkilling ~iS.pneumoniae~i faster than Levofloxacin. While efficacy of Levofloxacin,Gatifloxacin and Moxifloxacin against ~iM.catarrhalis~i and ~iH.influenzae~i demonstrated notdifference. About Moxifloxacin and Gatifloxacin, when administration multiple dosesregimen, decreased all 6 strains of microorganisms faster than single dose regimen.In the contrast Levofloxacin multiple doses regimen demonstrated similar killing ratewith single dose regimen.